Filing Flows › Comparisons › OCUL vs WVE
Ocular Therapeutix vs Wave Life Sciences: OCUL and WVE compared
Ocular Therapeutix is the larger company: $13.5M of revenue in its latest quarter (Q2 2026) against $13.2M for Wave Life Sciences (Q3 2026). Wave Life Sciences is growing faster (+73% against +0.1% a year earlier). Wave Life Sciences is more profitable, with an operating margin of -502.0% against -609.3%.
Where the money goes: OCUL and WVE
Ocular Therapeutix (OCUL) · Q2 2026
Ocular Therapeutix, Q2 2026: revenue $13.5M (+0.1% year over year), operating margin -609.3%, net loss $78.8M, operating cash flow −$67.3M. The chart follows the revenue to costs, profit and cash.
Wave Life Sciences (WVE) · Q3 2026
Wave Life Sciences, Q3 2026: revenue $13.2M (+73% year over year), operating margin -502.0%, net loss $61.9M, operating cash flow −$60.1M. The chart follows the revenue to costs, profit and cash.
| Ocular Therapeutix (OCUL) | Wave Life Sciences (WVE) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $13.5M | $13.2M |
| Revenue growth, Y/Y | +0.1% | +73% |
| Operating margin | -609.3% | -502.0% |
| Net earnings | −$78.8M | −$61.9M |
| Net margin | -584.5% | -470.5% |
| Operating cash flow | −$67.3M | −$60.1M |
Questions
Which is bigger, Ocular Therapeutix or Wave Life Sciences?
Ocular Therapeutix is the larger company: $13.5M of revenue in its latest quarter (Q2 2026) against $13.2M for Wave Life Sciences (Q3 2026).
Is Ocular Therapeutix or Wave Life Sciences growing faster?
Wave Life Sciences is growing faster (+73% against +0.1% a year earlier).
Which is more profitable, Ocular Therapeutix or Wave Life Sciences?
Wave Life Sciences is more profitable, with an operating margin of -502.0% against -609.3%.
More: Ocular Therapeutix earnings · how Ocular Therapeutix makes money · Wave Life Sciences earnings · how Wave Life Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 3, 2026; 10-Q filed Oct 27, 2026). Fiscal quarters can end on different dates. Not investment advice.